Zevra Therapeutics 3Q 2026: Revenue $37.76M, Net income $19.21M, EPS $0.26— 10-Q Summary

What happened

Zevra Therapeutics reported third-quarter 2026 revenue of $37.76M and net income of $19.21M, compared with $26.06M in revenue and a $544K net loss in the prior-year quarter. Diluted earnings per share were $0.26, versus a loss of $0.01 per share.

Confirmed

Global impact / market context

The higher revenue and swing to net income indicate stronger reported results, which may help fund Zevra’s drug programs. But the article does not establish how much cash is available or whether the improvement will continue; trial and regulatory work may still require spending.

Analyst inference

Nine-month revenue growth included higher U.S. product sales and EAP revenue, meaning revenue from an expanded-access program. The different sources may not develop at the same pace, while limited OLPRUVA sales and uncertainty around drug approvals and trials could affect future revenue and spending.

Analyst inference

What to watch

1. Watch whether revenue and net income remain above prior-year levels in later quarters; sustained growth would indicate the reported improvement is continuing. Analyst inference
2. Follow the requested re-examination of the European regulator’s negative opinion on arimoclomol, since its outcome could affect the drug’s regulatory path and sales prospects. Confirmed
3. Track MIPLYFFA enrollments and the celiprolol trial and FDA discussions, alongside OLPRUVA’s strategic review, as these developments may redirect spending and influence future revenue. Analyst inference

Evidence

• Original source link unavailable